Korean IBD patients (n=139) who were treated with infliximab were classified as either: primary response vs non-response, or sustained response vs loss of response. An association study was conducted using whole-exome sequencing data to identify genetic variants associated with infliximab response. Candidate variants were validated in 77 German patients with IBD.
Five candidate variants were found that were associated with primary non-response to infliximab (P<5×10−6). Of these variants, rs2228273 in ZNF133 was validated in German patients (combined P=6.49×10−7). The best genetic variant associated with loss of infliximab response was rs9144 (P=4.60×10−6). In multi-variate regression analysis, rs2228273 (P=2.10×10−5), concurrent azathioprine/6-mercaptopurine use, and body weight at the first infliximab use (<50 kg) were associated with primary non-response. In addition, the Crohn’s disease activity index (CDAI) at the time of first infliximab use, as well as rs9144 (P=0.001), were independently associated with loss of response in Crohn’s disease patients. These findings could provide insights to maximise the efficacy of infliximab therapy in IBD.
- Jung ES, et al. ECCO 2019, DOP55.
Posted on
Previous Article
« Upadacitinib: data from U-ACHIEVE and CELEST Next Article
Safety of thiopurine + allopurinol vs thiopurine monotherapy »
« Upadacitinib: data from U-ACHIEVE and CELEST Next Article
Safety of thiopurine + allopurinol vs thiopurine monotherapy »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
The right drug for the right patient
May 9, 2019
Pan-Janus kinase inhibitor TD-1473
May 9, 2019
Molecular effects of ustekinumab
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy